Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$5.14
-0.03-0.58%
At close: -
$5.14
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
AVITA Medical Analyst Ratings and Price Targets | NASDAQ:RCEL | Benzinga
AVITA Medical Inc has a consensus price target of $18.6 based on the ratings of 6 analysts. The high is $27 issued by B of A Securities on July 28, 2023. The low is $12 issued by Piper Sandler on November 8, 2024. The 3 most-recent analyst ratings were released by D. Boral Capital on June 10, 2025, June 6, 2025, and April 10, 2025, respectively. With an average price target of $20 between D. Boral Capital, there's an implied 289.11% upside for AVITA Medical Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
D. Boral Capital
Lake Street
Cantor Fitzgerald
Piper Sandler
B of A Securities
1calculated from analyst ratings
Analyst Ratings for AVITA Medical
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/10/2025 | Buy Now | 269.65% | D. Boral Capital | Jason Kolbert51% | $19 → $19 | Maintains | Buy | Get Alert |
| 06/06/2025 | Buy Now | 269.65% | D. Boral Capital | Jason Kolbert51% | $19 → $19 | Maintains | Buy | Get Alert |
| 04/10/2025 | Buy Now | 328.02% | D. Boral Capital | Jason Kolbert51% | $22 → $22 | Maintains | Buy | Get Alert |
| 04/04/2025 | Buy Now | 328.02% | D. Boral Capital | Jason Kolbert51% | $22 → $22 | Maintains | Buy | Get Alert |
| 03/18/2025 | Buy Now | 328.02% | D. Boral Capital | Jason Kolbert51% | $22 → $22 | Maintains | Buy | Get Alert |
| 02/20/2025 | Buy Now | 328.02% | D. Boral Capital | Jason Kolbert51% | $25 → $22 | Maintains | Buy | Get Alert |
| 02/14/2025 | Buy Now | 386.38% | D. Boral Capital | Jason Kolbert51% | $25 → $25 | Maintains | Buy | Get Alert |
| 01/08/2025 | Buy Now | 172.37% | Lake Street | Brooks O'Neil36% | $20 → $14 | Maintains | Buy | Get Alert |
| 01/08/2025 | Buy Now | 386.38% | D. Boral Capital | Jason Kolbert51% | $25 → $25 | Maintains | Buy | Get Alert |
| 12/24/2024 | Buy Now | 308.56% | Cantor Fitzgerald | Ross Osborn44% | $21 → $21 | Reiterates | Overweight → Overweight | Get Alert |
| 12/24/2024 | Buy Now | 386.38% | D. Boral Capital | Jason Kolbert51% | → $25 | Initiates | → Buy | Get Alert |
| 11/08/2024 | Buy Now | 133.46% | Piper Sandler | Matt O'Brien51% | $9 → $12 | Reiterates | Neutral → Neutral | Get Alert |
| 08/09/2024 | Buy Now | 308.56% | Cantor Fitzgerald | Ross Osborn44% | $21 → $21 | Reiterates | Overweight → Overweight | Get Alert |
| 05/14/2024 | Buy Now | 75.1% | Piper Sandler | Matt O'Brien51% | $21 → $9 | Downgrade | Overweight → Neutral | Get Alert |
| 05/14/2024 | Buy Now | 308.56% | Cantor Fitzgerald | Ross Osborn44% | $22 → $21 | Maintains | Overweight | Get Alert |
| 04/11/2024 | Buy Now | — | BTIG | Ryan Zimmerman70% | — | Downgrade | Buy → Neutral | Get Alert |
| 02/23/2024 | Buy Now | 308.56% | Piper Sandler | Matt O'Brien51% | $19 → $21 | Reiterates | Overweight → Overweight | Get Alert |
| 02/23/2024 | Buy Now | 386.38% | Cantor Fitzgerald | Ross Osborn44% | $22 → $25 | Maintains | Overweight | Get Alert |
| 01/19/2024 | Buy Now | 328.02% | Cantor Fitzgerald | Ross Osborn44% | $20 → $22 | Maintains | Overweight | Get Alert |
| 11/21/2023 | Buy Now | 289.11% | Cantor Fitzgerald | Ross Osborn44% | → $20 | Reiterates | Overweight → Overweight | Get Alert |
| 11/10/2023 | Buy Now | 269.65% | Piper Sandler | Matt O'Brien51% | $23 → $19 | Maintains | Overweight | Get Alert |
| 10/19/2023 | Buy Now | 405.84% | Cantor Fitzgerald | Ross Osborn44% | → $26 | Reiterates | Overweight → Overweight | Get Alert |
| 09/26/2023 | Buy Now | 405.84% | Cantor Fitzgerald | Ross Osborn44% | → $26 | Reiterates | Overweight → Overweight | Get Alert |
| 08/22/2023 | Buy Now | 405.84% | Cantor Fitzgerald | Ross Osborn44% | → $26 | Reiterates | Overweight → Overweight | Get Alert |
| 08/11/2023 | Buy Now | 347.47% | Piper Sandler | Matt O'Brien51% | $18.5 → $23 | Maintains | Overweight | Get Alert |
| 07/28/2023 | Buy Now | 425.29% | B of A Securities | Lyanne Harrison51% | $18 → $27 | Maintains | Buy | Get Alert |
| 07/13/2023 | Buy Now | 678.21% | Lake Street | Brooks O'Neil36% | $30 → $40 | Maintains | Buy | Get Alert |
| 06/27/2023 | Buy Now | 347.47% | Cantor Fitzgerald | Ross Osborn44% | → $23 | Initiates | → Overweight | Get Alert |
| 06/26/2023 | Buy Now | 483.66% | Lake Street | Brooks O'Neil36% | $30 → $30 | Maintains | Buy | Get Alert |
| 06/09/2023 | Buy Now | 483.66% | Lake Street | Brooks O'Neil36% | $30 → $30 | Maintains | Buy | Get Alert |
| 05/12/2023 | Buy Now | 483.66% | Lake Street | Brooks O'Neil36% | $30 → $30 | Maintains | Buy | Get Alert |
| 05/12/2023 | Buy Now | 259.92% | Piper Sandler | Matt O'Brien51% | $16 → $18.5 | Maintains | Overweight | Get Alert |
| 04/17/2023 | Buy Now | 269.65% | BTIG | Ryan Zimmerman70% | $16 → $19 | Maintains | Buy | Get Alert |
| 02/24/2023 | Buy Now | 483.66% | Lake Street | Brooks O'Neil36% | → $30 | Maintains | Buy | Get Alert |
FAQ
What is the target price for AVITA Medical (RCEL) stock?
The latest price target for AVITA Medical (NASDAQ:RCEL) was reported by D. Boral Capital on June 10, 2025. The analyst firm set a price target for $19.00 expecting RCEL to rise to within 12 months (a possible 269.65% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for AVITA Medical (RCEL)?
The latest analyst rating for AVITA Medical (NASDAQ:RCEL) was provided by D. Boral Capital, and AVITA Medical maintained their buy rating.
When was the last upgrade for AVITA Medical (RCEL)?
There is no last upgrade for AVITA Medical
When was the last downgrade for AVITA Medical (RCEL)?
The last downgrade for AVITA Medical Inc happened on May 14, 2024 when Piper Sandler changed their price target from $21 to $9 for AVITA Medical Inc.
When is the next analyst rating going to be posted or updated for AVITA Medical (RCEL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AVITA Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AVITA Medical was filed on June 10, 2025 so you should expect the next rating to be made available sometime around June 10, 2026.
Is the Analyst Rating AVITA Medical (RCEL) correct?
While ratings are subjective and will change, the latest AVITA Medical (RCEL) rating was a maintained with a price target of $19.00 to $19.00. The current price AVITA Medical (RCEL) is trading at is $5.14, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
